Ethan Wright
5516815
Wednesday March 30, 2011
ENSC 201
Word Count: 1624
The presence of pharmaceuticals and personal care products (PPCPs) in
municipal effluents has raised concern as to the potential impact of pharmaceutical
compounds on human health and the environment. There much information
regarding the health effects of pharmaceuticals at therapeutic levels, but
little information is available on the effects of exposure to PPCPs at sub- therapeutic concentrations. This is largely due to the fact that detected levels of
pharmaceutically active compounds in aquatic environments and municipal water
resources are minute and is reinforced by the belief that existing wastewater
treatment plants (WWTP) are effective at removing pollutants. Difficulties in
targeting specific exposure routes, applying preventative measures, and identifying
pharmaceuticals-of-concern have acted as barriers to a solution. Current scientific
data does not prove that the presences of pharmaceuticals in municipal effluents are
detrimental to human health and the environment. While inherently a health issue,
significant considerations must be given to the political practicality and economics
of applying significant policy initiatives and risk management or mitigation efforts.
Until questions regarding pollution sources, locations, removal methods and
compounds of concern can be solved with supporting scientific evidence; PPCPs
in water will remain an area of civic concern with limited economic or legislative
Pharmaceutically active chemical compounds have knowingly been
released into aquatic environments and municipal drinking water sources for more
than 20 years (Kleywegt et al., 2007). Before a legislative strategy can allocate
economic resources towards reducing the health risk of low concentrations of
pharmaceuticals in water, progress in knowledge gaps for identifying high-source
locations of pollution and detecting pharmaceuticals-of-concern and special interest
must be made. Pharmaceuticals are manufactured for the purpose of causing
biological effects. Wide ranges of human and veterinary medicines, including
antibiotics, contraceptives, antifungals, and parasiticides, are produced and used in
Canada in the thousands of tons each year (Boxall, 2004, 1110). Veterinary
medicines, unlike human medicines (which usually find their way to municipal
waste treatment plants), can directly enter the soil and surface waters thereby
increasing the size and scope of source distribution (Boxall, 2004, 1110). Once
released into the environment, pharmaceuticals are redistributed to aquatic and
terrestrial communities by air, water, and sediment transport (Boxall, 2004; 1112).
Typical routes of entry (see Appendix 1) into the environment include
pharmaceutical residues released during the manufacturing process, human
excretions and waste, direct release, wastewater runoff, inappropriate disposals of
containers, aquatic and terrestrial treatments, and more (Boxall, 2004, 1110). The
sources of pharmaceutical exposure can be broken down into two categories,
industrial and domestic wastes. Domestic pharmaceutical waste constitutes the
largest portion of contaminants in municipal waters with the majority of pollutants
collecting in septic tanks and landfills (Kleywegt et. Al., 2007). While the sources of
PPCP exposure are known, there is currently no legitimate monitoring framework
or removal method for eliminating PPCPs from entering WWTPs and surface water
at the root of the problem – domestic consumption. Without a consistent framework
for analyzing PPCP entry methods including areas of significant concentrations and
details on specific chemical entries from specific entry points, efforts to mediate
potential health effects by directly